Latest news

4,996 article downloads per month. Click to see more open access visibility statistics.

Journal newsletter sent to subscribers in week 37, 2009. Follow link to see newsletter summary.  Register to receive newsletters.

Journal newsletter sent to subscribers in week 36, 2009. Register to receive future newsletters. 

Journal newsletter sent to subscribers in week 35, 2009. Register to receive future newsletters. 

Journal newsletter sent to subscribers in week 34, 2009. Register to receive future newsletters. 

Journal newsletter sent to subscribers in week 33, 2009. Register to receive future newsletters. 

Journal newsletter sent to subscribers in week 32, 2009. Register to receive future newsletters.

Journal newsletter sent to subscribers in week 31, 2009. Register to receive future newsletters. 

Journal newsletter sent to subscribers in week 30, 2009. Register to receive future newsletters. 

Journal newsletter sent to subscribers in week 29, 2009. Register to receive future newsletters.

Journal newsletter sent to subscribers in week 28, 2009. Register to receive future newsletters.

Journal newsletter sent to subscribers in week 27, 2009. Register to receive future newsletters. 

The Editor in Chief has issued a new call for papers.  Read it here.

Journal newsletter sent to subscribers in week 26, 2009. Register to receive future newsletters. 

Journal newsletter sent to subscribers in week 24, 2009. Register to receive future newsletters.

Journal newsletter sent to subscribers in week 23, 2009. Register to receive future newsletters.

Journal newsletter sent to subscribers in week 21, 2009. Register to receive future newsletters.

Journal newsletter sent to subscribers in week 19, 2009. Register to receive future newsletters.

Follow this journal on Twitter

Journal newsletter sent to subscribers in week 17, 2009.  Register to receive future newsletters.

Journal newsletter sent to subscribers in week 16, 2009.  Register to receive future newsletters.

Journal newsletter sent to subscribers in week 15, 2009.  Register to receive future newsletters. 

This journal has been accepted for indexing in DOAJ.

Journal newsletter sent to subscribers in week 14, 2009.  Register to receive future newsletters.

Journal newsletter sent to subscribers in week 13, 2009.  Register to receive future newsletters.

Journal newsletter sent to subscribers in week 10, 2009.  Register to receive future newsletters. 

New call for papers sent to newsletter subscribers in week 8 2009. Readers who wish to be elligible to receive CFPs should subscribe to the newsletter.

Peer reviewers are sought. Click here to apply or to update your details.

Journal overview

Aims and scope:

Clinical Medicine Insights: Therapeutics focuses on the role of therapeutics in human clinical medicine.

Former title:

Prior to 1/1/2010 this journal was titled Clinical Medicine: Therapeutics (ISSN 1179-1713.) 

Editorial standards and procedures:

Submissions, excluding editorials, letters to the editor and dedications, will be peer reviewed by two reviewers.  Reviewers are required to provide fair, balanced and constructive reports.  

Under our Fairness in Peer Review Policy authors may appeal against reviewers' recommendations which are ill-founded, unobjective or unfair.  Appeals are considered by the Editor in Chief or Associate Editor.

Papers are not sent to peer reviewers following submission of a revised manuscript. Editorial decisions on re-submitted papers are based on the author's response to the initial peer review report.

Indexing:

This journal is indexed by:

• DOAJ 
• OAIster
  

National Institutes of Health Public Access Policy compliant:

As of April 7 2008, the US NIH Public Access Policy requires that all peer reviewed articles resulting from research carried out with NIH funding be deposited in the Pubmed Central archive.

If you are an NIH employee or grantee Libertas Academica will ensure that you comply with the policy by depositing your paper at Pubmed Central on your behalf. 

Information for authors

Call for papers:

Read the Editor in Chief's latest call for papers here.

Submission types accepted:

Submissions of the following types of manuscripts are accepted:

• Original research articles.
• Reviews: comprehensive, authoritative, descriptions of any subject within the journal's scope. They may cover basic science and clinical reviews, ethics, pro/con debates, and equipment reviews.
• Commentaries: focused and opinionated articles on any subject within the journal's scope. These articles are usually related to a contemporary issue.
• Hypotheses: articles that present an original hypothesis backed solely by previously published results rather than any new evidence. They should outline significant progress in thinking that would also be testable.
• Letters to the Editor: these can be either a re-analysis of a previously published article, or a response to such a re-analysis from the authors of the original publication.
• Methodology articles: these discuss a new experimental method, test or procedure. The article must describe a demonstrable advance on what is currently available. The method needs to have been well tested and ideally, but not necessarily, used in a way that proves its value.
• Short reports: brief reports of data from original research.
• Meeting reports: a report pertaining to activity at a meeting or conference Articles published in this journal are immediately available without delay upon publication and enjoy substantial visibility.
• Case reports: reports of clinical cases that can be educational, describe a diagnostic or therapeutic dilemma, suggest an association, or present an important adverse reaction. Case reports must meet appropriate ethical standards.

All submissions are subject to prompt, objective and fair peer review in compliance with our Fairness in Peer Review Policy.  Copyright in published articles remains with the author(s).  Authors are continually informed of the progress of their paper and our staff are friendly and responsive. 

One author recently wrote: "I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely."

Criteria for publication: 

Publication is dependent on peer reviewers' judgement of papers.  Reviewers are asked to provide thoughtful and unbiased feedback to authors to ensure that the conclusions of papers are valid and manuscripts achieve reasonable standards of scholarliness and intelligibility. 

Previous work in the field must be acknowledged and papers should read without unreasonable difficulty.  Papers should fit comfortably within the scope of the journal.

Reviewers are asked to act in a fair, objective and constructive manner which maintains quality standards and helps authors to communicate their research.  They are instructed that in areas of genuinely novel research issues may be raised which cannot immediately be resolved and that absolutely rigorous validation of data may therefore not be possible. 

More information on the role of peer reviewers is available on the information for reviewers page.  Where authors consider that reviewers have made recommendations which are unreasonable, unobjective or ill-founded they may appeal them to the Editor in Chief or Associate Editor under our Fairness in Peer Review Policy.

Articles submitted to other journals:

We are willing to consider papers which have been peer reviewed by other journals but not accepted for publication. 

Services for authors:

Prior to peer review of your paper we can:

• Have your paper's reference style revised to meet our requirements,
• Have your paper's English revised by specialist English-speaking technical editors.

After peer review of your paper we can:

• Have your paper revised in accordance with peer reviewer's recommendations and have a summary of responses to the reviewers created by our specialist external substantive editors,
• Provide bound reprints of your article in colour or black and white ,
• Provide online-early rapid publication if your paper prior to typesetting.

What other authors have said:

Libertas Academica actively requests, receives and acts upon feedback from authors, readers and editorial boards.  Here's what some recent authors have said about us:

"Within a couple of days the reviewers had been procured and the manuscript was out."

"The communication between your staff and me has been terrific.  Whenever progress is made with the manuscript, I receive notice.  Quite honestly, I've never had such complete communication with a journal."

"LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought."

Article processing fees:

Unsolicitied submissions to this journal are subject to an article processing fee if they are accepted for publication.  Article processing fees are used to fund the processing of your paper and development of the journal.  Article processing fees are the only compulsory charge you will face and do not vary according to word count, page count, colour figures or any other factor.  There is no additional charge for the author(s) to make any use of their article and no charge to readers to access it.

Full fee waivers are available for authors working in undeveloped nations and partial discounts of 20-50% are available to authors in other nations.  Authors must be able to verifiably demonstrate their suitability for a discount or waiver.  Availability of waivers and discounts is subject to monthly availability and is given at the publisher's discretion.  Waivers and discounts must be applied for prior to submission.  Neither are available after submission.

Register as a peer reviewer:

Do you wish to register as a peer reviewer?  Or are you already a registered peer reviewer but you need to update your contact details?   To register or update your details visit the peer reviewer registration form. 

Applicants must be able to demonstrate at least five years of continuous experience in the journal's subject area including at least two in the previous 24 months.

Editor in Chief profile

Dr Garry M. Walsh, Reader in Immunity and Inflammation and Principal Investigator, Asthmatic and Allergic Inflammation Group, School of Medicine, Institute of Medical Sciences, University of Aberdeen, Aberdeen, U.K.

Dr Walsh’s research career spans 25 years during which his work has focused on the elucidation of the molecular mechanisms controlling the initiation and resolution of the inflammatory processes underlying asthma, COPD and allergic disease with an emphasis on the role played by airway epithelial cells and eosinophils. Dr Walsh has published in both basic and clinical science, including several seminal papers on cell death, apoptotic cell disposal and the clinical relevance of apoptotic cell clearance.

He has secured over £2 million in research funding as principal investigator from Research Charities including the Wellcome Trust, the Medical Research Council and industry. Dr Walsh has published more than 55 peer reviewed articles and over 50 editorials, reviews and book chapters; these have been cited over 2000 times. He has been an invited speaker and/or chairman at more than 30 prestigious international meetings. Dr Walsh is founding Editor-in-Chief of Therapeutics & Clinical Risk Management and serves as editorial board member for seven international peer-reviewed journals.   He is a regular reviewer for over thirty other journals and is a member of many professional organizations and committees, including the Collegium Internationale Allergologicum.  Dr Walsh is Visiting Professor of Immunity and inflammation in the Department of Clinical Medicine at Trinity College, Dublin, Ireland.

>> Dr Walsh's latest call for papers

Editorial Board

Mahboob Alam, MD
Fellow, Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA

Karna Dev Bardhan, PhD
Consultant Physician and Gastroenterologist, Generam Medicine and Gastroenterology, Rotherham General Hospital, Rotherham, UK

Deirdre R Coombe, PhD
Associate Professor, Biomedical Sciences, Curtin University of Technology, Perth, Western Australia, Australia

David R P Guay, PhD
Professor, Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA

Jagdish N. Sharma, PhD
Professor, Applied Therapeutics and Pharmacology, Faculty of Pharmacy, Health Sciences Centre, Kuwait University, Kuwait

Neil Campbell Thomson, PhD
Professor of Respiratory Medicine, Division of Immunology, Infection and Immunology, University of Glasgow & Gartnavel General Hospital, Glasgow, UK

Wang De Yun, PhD
Associate Professor, Otolaryngology, National University of Singapore, Singapore

Xiangdong Wang, PhD
Professor of Medicine, Respiratory Medicine, Zhongshan Hospital, Shanghai, China

Join an editorial board or update your details:

Related journals